Abhyankar, DBajpai, SSaikia, TGopal, RNair, C NAdvani, S H2001-08-122009-05-312001-08-122009-05-312001-08-12Abhyankar D, Bajpai S, Saikia T, Gopal R, Nair CN, Advani SH. 2-CdA in the treatment of hairy cell leukaemia. Journal of the Association of Physicians of India. 2001 Aug; 49(): 785-7http://imsear.searo.who.int/handle/123456789/91940INTRODUCTION: Hairy cell leukaemia (HCL) is a rare lymphoproliferative disorder. Treatment options available are splenectomy, interferon, DCF and 2-CdA. 2-CdA is considered to have curative potential as proved by the other studies. METHODS: We gave 2-CdA in a dose of 0.09/kg/day as a continuous infusion in sixteen patients of hairy cell leukaemia. RESULTS: Three patients developed neutropenia post transfusion. At the end of three months all patients were in remission. Two patients relapsed at the median follow-up of 15 months. CONCLUSION: 2-CdA in HCL can achieve complete remission, prolonged survival and care as well.eng2-Chloroadenosine --adverse effectsAdultAntimetabolites, Antineoplastic --adverse effectsDeoxyadenosines --adverse effectsFemaleHumansLeukemia, Hairy Cell --drug therapyMaleMiddle AgedNeutropenia --chemically inducedSurvival RateTreatment OutcomeClinical Trial